|
1
|
Saini A, Kumar M, Bhatt S, Saini V and
Malik A: Cancer causes and treatments. Int J Pharm Sci Res.
11:3121–3134. 2020.
|
|
2
|
Fatima N, Liu L, Hong S and Ahmed H:
Prediction of breast cancer, comparative review of machine learning
techniques, and their analysis. IEEE Access. 8:150360–150376.
2020.
|
|
3
|
Mathur R, Jha NK, Saini G, Jha SK, Shukla
SP, Filipejová Z, Kesari KK, Iqbal D, Nand P, Upadhye VJ, et al:
Epigenetic factors in breast cancer therapy. Front Genet.
13(886487)2022.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mehrotra R and Yadav K: Breast cancer in
India: Present scenario and the challenges ahead. World J Clin
Oncol. 13(209)2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Mohanad M, Hamza HM, Bahnassy AA, Shaarawy
S, Ahmed O, El-Mezayen HA, Ayad EG, Tahoun N and Abdellateif MS:
Molecular profiling of breast cancer methylation pattern in triple
negative versus non-triple negative breast cancer. Sci Rep.
15(6894)2025.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Buocikova V, Rios-Mondragon I, Pilalis E,
Chatziioannou A, Miklikova S, Mego M, Pajuste K, Rucins M, Yamani
NE, Longhin EM, et al: Epigenetics in breast cancer therapy-new
strategies and future nanomedicine perspectives. Cancers (Basel).
12(3622)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Klibaner-Schiff E, Simonin EM, Akdis CA,
Cheong A, Johnson MM, Karagas MR, Kirsh S, Kline O, Mazumdar M,
Oken E, et al: Environmental exposures influence multigenerational
epigenetic transmission. Clin Epigenetics. 16(145)2024.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Kang Z, Wang J, Liu J, Du L and Liu X:
Epigenetic modifications in breast cancer: From immune escape
mechanisms to therapeutic target discovery. Front Immunol.
16(1584087)2025.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Watanabe Y, Maeda I, Oikawa R, Wu W,
Tsuchiya K, Miyoshi Y, Itoh F, Tsugawa KI and Ohta T: Aberrant DNA
methylation status of DNA repair genes in breast cancer treated
with neoadjuvant chemotherapy. Genes Cells. 18:1120–1130.
2013.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Chiou YS, Li S, Ho CT and Pan MH:
Prevention of breast cancer by natural phytochemicals: Focusing on
molecular targets and combinational strategy. Mol Nutr Food Res.
62(e1800392)2018.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Abbasi BA, Iqbal J, Mahmood T, Khalil AT,
Ali B, Kanwal S, Shah SA and Ahmad R: Role of dietary
phytochemicals in modulation of miRNA expression: Natural swords
combating breast cancer. Asian Pac J Trop Med. 11:501–509.
2018.
|
|
12
|
Sohel M, Aktar S, Biswas P, Amin MA,
Hossain MA, Ahmed N, Mim MIH, Islam F and Mamun AA: Exploring the
anti-cancer potential of dietary phytochemicals for the patients
with breast cancer: A comprehensive review. Cancer Med.
12:14556–14583. 2023.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Thuy LHA, Thuan LD and Phuong TK: DNA
hypermethylation in breast cancer. In: Breast Cancer-From Biology
to Medicine. IntechOpen, 2017.
|
|
14
|
Flores-García LC, Rubio K, Ibarra-Sierra
E, Silva-Cázares MB, Palma-Flores C and López-Camarillo C:
Epigenetic and transcriptional reprogramming in 3D culture models
in breast cancer. Cancers (Basel). 17(3830)2025.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Park M, Kim D, Ko S, Kim A, Mo K and Yoon
H: Breast cancer metastasis: Mechanisms and therapeutic
implications. Int J Mol Sci. 23(6806)2022.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Smith ZD, Hetzel S and Meissner A: DNA
methylation in mammalian development and disease. Nat Rev Genet.
26:7–30. 2025.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Karami Fath M, Azargoonjahromi A, Kiani A,
Jalalifar F, Osati P, Akbari Oryani M, Shakeri F, Nasirzadeh F,
Khalesi B, Nabi-Afjadi M, et al: The role of epigenetic
modifications in drug resistance and treatment of breast cancer.
Cell Mol Biol Lett. 27(52)2022.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Jha AK, Nikbakht M, Jain V, Sehgal A,
Capalash N and Kaur J: Promoter hypermethylation of p73 and p53
genes in cervical cancer patients among north Indian population.
Mol Biol Rep. 39:9145–9157. 2012.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Agarwal N and Jha AK: DNA hypermethylation
of tumor suppressor genes among oral squamous cell carcinoma
patients: A prominent diagnostic biomarker. Mol Biol Rep.
52(44)2024.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Fu J, Qin T, Li C, Zhu J, Ding Y, Zhou M,
Yang Q, Liu X, Zhou J and Chen F: Research progress of LINE-1 in
the diagnosis, prognosis, and treatment of gynecologic tumors.
Front Oncol. 13(1201568)2023.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Chen C, Wang Z, Ding Y, Wang L, Wang S,
Wang H and Qin Y: DNA methylation: From cancer biology to clinical
perspectives. Front Biosci (Landmark Ed). 27(326)2022.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Besselink N, Keijer J, Vermeulen C,
Boymans S, de Ridder J, van Hoeck A, Cuppen E and Kuijk E: The
genome-wide mutational consequences of DNA hypomethylation. Sci
Rep. 13(6874)2023.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Jung I, An J and Ko M: Epigenetic
regulators of DNA cytosine modification: Promising targets for
cancer therapy. Biomedicines. 11(654)2023.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Heery R and Schaefer MH: DNA methylation
variation along the cancer epigenome and the identification of
novel epigenetic driver events. Nucleic Acids Res. 49:12692–12705.
2021.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Dunican DS, Mjoseng HK, Duthie L, Flyamer
IM, Bickmore WA and Meehan RR: Bivalent promoter hypermethylation
in cancer is linked to the H327me3/H3K4me3 ratio in embryonic stem
cells. BMC Biol. 18(25)2020.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Vietri MT, D'elia G, Benincasa G, Ferraro
G, Caliendo G, Nicoletti GF and Napoli C: DNA methylation and
breast cancer: A way forward (Review). Int J Oncol.
59(98)2021.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Duan X, Xing Z, Qiao L, Qin S, Zhao X,
Gong Y and Li X: The role of histone post-translational
modifications in cancer and cancer immunity: Functions, mechanisms
and therapeutic implications. Front Immunol.
15(1495221)2024.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Gong P, Guo Z, Wang S, Gao S and Cao Q:
Histone phosphorylation in DNA damage response. Int J Mol Sci.
26(2405)2025.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Fang Z, Wang X, Sun X, Hu W and Miao QR:
The role of histone protein acetylation in regulating endothelial
function. Front Cell Dev Biol. 9(672447)2021.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Baweja L and Wereszczynski J: Mechanistic
basis for the opposing effects of H2A and H2B ubiquitination on
nucleosome stability and dynamics. bioRxiv [Preprint]:
2025.02.13.638112, 2025.
|
|
31
|
Ryu HY and Hochstrasser M: Histone
sumoylation and chromatin dynamics. Nucleic Acids Res.
49:6043–6052. 2021.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Millán-Zambrano G, Burton A, Bannister AJ
and Schneider R: Histone post-translational modifications-cause and
consequence of genome function. Nat Rev Genet. 23:563–580.
2022.PubMed/NCBI View Article : Google Scholar
|
|
33
|
George TP, Subramanian S and Supriya MH: A
brief review of noncoding RNA. Egypt J Med Hum Genet.
25(98)2024.
|
|
34
|
Amelio I, Bernassola F and Candi E:
Emerging roles of long non-coding RNAs in breast cancer biology and
management. Semin Cancer Biol. 72:36–45. 2021.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Keyvani-Ghamsari S, Khorsandi K, Rasul A
and Zaman MK: Current understanding of epigenetics mechanism as a
novel target in reducing cancer stem cells resistance. Clin
Epigenetics. 13(120)2021.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Jouravleva K and Zamore PD: A guide to the
biogenesis and functions of endogenous small non-coding RNAs in
animals. Nat Rev Mol Cell Biol. 26:347–370. 2025.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Xiong Q and Zhang Y: Small RNA
modifications: Regulatory molecules and potential applications. J
Hematol Oncol. 16(64)2023.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Lu C, Wei D, Zhang Y, Wang P and Zhang W:
Long non-coding RNAs as potential diagnostic and prognostic
biomarkers in breast cancer: progress and prospects. Front Oncol.
11(710538)2021.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Hopkins JL, Lan L and Zou L: DNA repair
defects in cancer and therapeutic opportunities. Genes Dev.
36:278–293. 2022.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Kundu S, Sarkar S, Ghosh S and Chowdhury
AA: DNA methylation as an oncogenic driver in breast cancer:
Therapeutic targeting via epigenetic reprogramming of DNA
methyltransferases. Biochem Pharmacol. 242(117313)2025.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Moelans CB, Verschuur-Maes AH and Van
Diest PJ: Frequent promoter hypermethylation of BRCA2, CDH13, MSH6,
PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast
cancer. J Pathol. 225:222–231. 2011.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Aravind Kumar M, Naushad SM, Narasimgu N,
Nagaraju Naik S, Kadali S, Shanker U and Lakshmi Narasu M: Whole
exome sequencing of breast cancer (TNBC) cases from India:
Association of MSH6 and BRIP1 variants with TNBC risk and oxidative
DNA damage. Mol Biol Rep. 45:1413–1419. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Zou R, Zhong X, Wang C, Sun H, Wang S, Lin
L, Sun S, Tong C, Luo H, Gao P, et al: MDC1 enhances estrogen
receptor-mediated transactivation and contributes to breast cancer
suppression. Int J Biol Sci. 11:992–1005. 2015.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Torres Esteban M: Structural and
Functional Characterization of Two Phosphorylation Site Clusters in
the DNA Damage Response Adaptor Protein MDC1. Doctoral
Dissertation, University of Zurich, 2024.
|
|
45
|
Kelliher J, Ghosal G and Leung JWC: New
answers to the old RIDDLE: RNF168 and the DNA damage response
pathway. FEBS J. 289:2467–2480. 2022.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Xie T, Qin H, Yuan Z, Zhang Y, Li X and
Zheng L: Emerging roles of RNF168 in tumor progression. Molecules.
28(1417)2023.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Pettitt S, Proszek P, Torga G, Gulati A,
Llop-Guevara A, Jank P, Felder B, Rodriguez A, Cooke S,
Garcia-Murillas I, et al: 435 (PB423): Persistence of BRCA1 and
RAD51C methylation after neoadjuvant chemotherapy in high risk
TNBC. Eur J Cancer. 211 (Suppl 1)(S114944)2024.
|
|
48
|
Tabano S, Azzollini J, Pesenti C, Lovati
S, Costanza J, Fontana L, Peissel B, Miozzo M and Manoukian S:
Analysis of BRCA1 and RAD51C promoter methylation in Italian
families at high-risk of breast and ovarian cancer. Cancers
(Basel). 12(910)2020.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Malik SS, Zia A, Mubarik S, Masood N,
Rashid S, Sherrard A, Khan MB and Khadim MT: Correlation of MLH1
polymorphisms, survival statistics, in silico assessment and gene
downregulation with clinical outcomes among breast cancer cases.
Mol Biol Rep. 47:683–692. 2020.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Dasgupta H, Islam S, Alam N, Roy A,
Roychoudhury S and Panda CK: Hypomethylation of mismatch repair
genes MLH1 and MSH2 is associated with chemotolerance of breast
carcinoma: Clinical significance. J Surg Oncol. 119:88–100.
2019.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Heng J, Zhang F, Guo X, Tang L, Peng L,
Luo X, Xu X, Wang S, Dai L and Wang J: Integrated analysis of
promoter methylation and expression of telomere related genes in
breast cancer. Oncotarget. 8(25442)2017.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Abad E, Civit L, Potesil D, Zdrahal Z and
Lyakhovich A: Enhanced DNA damage response through RAD50 in triple
negative breast cancer resistant and cancer stem-like cells
contributes to chemoresistance. FEBS J. 288:2184–2202.
2021.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Borde V: The multiple roles of the Mre11
complex for meiotic recombination. Chromosome Res. 15:551–563.
2007.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Lu R, Zhang H, Jiang YN, Wang ZQ, Sun L
and Zhou ZW: Post-translational modification of MRE11: Its
implication in DDR and diseases. Genes (Basel).
12(1158)2021.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Block-Schmidt AS, Dukowic-Schulze S,
Wanieck K, Reidt W and Puchta H: BRCC36A is epistatic to BRCA1 in
DNA crosslink repair and homologous recombination in Arabidopsis
thaliana. Nucleic Acids Res. 39:146–154. 2011.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Rabl J, Bunker RD, Schenk AD, Cavadini S,
Gill ME, Abdulrahman W, Andrés-Pons A, Luijsterburg MS, Ibrahim
AFM, Branigan E, et al: Structural basis of BRCC36 function in DNA
repair and immune regulation. Mol Cell. 75:483–497.e9.
2019.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Rosen EM, Fan S, Pestell RG and Goldberg
ID: BRCA1 gene in breast cancer. J Cell Physiol. 196:19–41.
2003.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Tarsounas M and Sung P: The
antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.
Nat Rev Mol Cell Biol. 21:284–299. 2020.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Stefansson OA and Esteller M: Epigenetic
modifications in breast cancer and their role in personalized
medicine. Am J Pathol. 183:1052–1063. 2013.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Fishchuk L, Rossokha Z, Lobanova O,
Cheshuk V, Vereshchako R, Vershyhora V, Medvedieva N, Dubitskaa O
and Gorovenko N: Hypermethylation of the BRCA2 gene promoter and
its co-hypermethylation with the BRCA1 gene promoter in patients
with breast cancer. Cancer Biomark. 40:275–283. 2024.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Pauty J, Rodrigue A, Couturier A, Buisson
R and Masson JY: Exploring the roles of PALB2 at the crossroads of
DNA repair and cancer. Biochem J. 460:331–342. 2014.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Potapova A, Hoffman AM, Godwin AK,
Al-Saleem T and Cairns P: Promoter hypermethylation of the PALB2
susceptibility gene in inherited and sporadic breast and ovarian
cancer. Cancer Res. 68:998–1002. 2008.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Khanna KK: Cancer risk and the ATM gene: A
continuing debate. J Natl Cancer Inst. 92:795–802. 2000.PubMed/NCBI View Article : Google Scholar
|
|
64
|
He C, Kawaguchi K and Toi M: DNA damage
repair functions and targeted treatment in breast cancer. Breast
Cancer. 27:355–362. 2020.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Vo QN, Kim WJ, Cvitanovic L, Boudreau DA,
Ginzinger DG and Brown KD: Erratum: The ATM gene is a target for
epigenetic silencing in locally advanced breast cancer. Oncogene.
24(1964)2005.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Zhou T, Yi F, Wang Z, Guo Q, Liu J, Bai N,
Li X, Dong X, Ren L, Cao L and Song X: The functions of DNA damage
factor RNF8 in the pathogenesis and progression of cancer. Int J
Biol Sci. 15:909–918. 2019.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Lee HJ, Li CF, Ruan D, Powers S, Thompson
PA, Frohman MA and Chan CH: The DNA damage transducer RNF8
facilitates cancer chemoresistance and progression through twist
activation. Mol Cell. 63:1021–1033. 2016.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Hacking S, Chou C, Baykara Y, Wang Y, Uzun
A and Gamsiz Uzun ED: MMR deficiency defines distinct molecular
subtype of breast cancer with histone proteomic networks. Int J Mol
Sci. 24(5327)2023.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Patel PS, Abraham KJ, Guturi KK, Halaby
MJ, Khan Z, Palomero L, Ho B, Duan S, St-Germain J, Algouneh A, et
al: RNF168 regulates R-loop resolution and genomic stability in
BRCA1/2-deficient tumors. J Clin Invest.
131(e140105)2021.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Liu H and Weng J: A pan-cancer
bioinformatic analysis of RAD51 regarding the values for diagnosis,
prognosis, and therapeutic prediction. Front Oncol.
12(858756)2022.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Yan Y, Wang Y, Tang J, Liu X, Wang J, Song
G and Li H: Comprehensive analysis of oncogenic somatic alterations
of mismatch repair gene in breast cancer patients. Bioengineering
(Basel). 12(426)2025.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Karamat U and Ejaz S: Overexpression of
RAD50 is the marker of poor prognosis and drug resistance in breast
cancer patients. Current Cancer Drug Targets. 21:163–176.
2021.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Alblihy A, Shoqafi A, Toss MS, Algethami
M, Harris AE, Jeyapalan JN, Abdel-Fatah T, Servante J, Chan SYT,
Green A, et al: Untangling the clinicopathological significance of
MRE11-RAD50-NBS1 complex in sporadic breast cancers. NPJ Breast
Cancer. 7(143)2021.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Mohamed RI, Bargal SA, Mekawy AS,
El-Shiekh I, Tuncbag N, Ahmed AS, Badr E and Elserafy M: The
overexpression of DNA repair genes in invasive ductal and lobular
breast carcinomas: Insights on individual variations and precision
medicine. PLoS One. 16(e0247837)2021.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Glodzik D, Bosch A, Hartman J, Aine M,
Vallon-Christersson J, Reuterswärd C, Karlsson A, Mitra S, Niméus
E, Holm K, et al: Comprehensive molecular comparison of BRCA1
hypermethylated and BRCA1 mutated triple negative breast cancers.
Nat Commun. 11(3747)2020.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Pang JMB, Deb S, Takano EA, Byrne DJ, Jene
N, Boulghourjian A, Holliday A, Millar E, Lee CS, O'Toole SA, et
al: Methylation profiling of ductal carcinoma in situ and its
relationship to histopathological features. Breast Cancer Res.
16(423)2014.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Scott CM, Joo JE, O'Callaghan N, Buchanan
DD, Clendenning M, Giles GG, Hopper JL, Wong EM and Southey MC:
Methylation of breast cancer predisposition genes in early-onset
breast cancer: Australian breast cancer family registry. PLoS One.
11(e0165436)2016.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Knijnenburg TA, Wang L, Zimmermann MT,
Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS,
et al: Genomic and molecular landscape of DNA damage repair
deficiency across the cancer genome atlas. Cell Rep. 23:239–254.
2018.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Liu C, Kuang J, Wang Y, Duan T, Min L, Lu
C, Zhang T, Chen R, Wu Y and Zhu L: A functional reference map of
the RNF8 interactome in cancer. Biol Direct. 17(17)2022.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Jayakumari S: Phytochemicals and
pharmaceutical: Overview: Recent progress and future applications.
In: Advances in Pharmaceutical Biotechnology. Springer Singapore,
pp163-173, 2020.
|
|
81
|
Kumar A, P N, Kumar M, Jose A, Tomer V, Oz
E, Proestos C, Zeng M, Elobeid T, K S and Oz F: Major
phytochemicals: Recent advances in health benefits and extraction
method. Molecules. 28(887)2023.PubMed/NCBI View Article : Google Scholar
|
|
82
|
Bhattacharya T, Dutta S, Akter R, Rahman
MH, Karthika C, Nagaswarupa HP, Murthy HCA, Fratila O, Brata R and
Bungau S: Role of phytonutrients in nutrigenetics and nutrigenomics
perspective in curing breast cancer. Biomolecules.
11(1176)2021.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Pop S, Enciu AM, Tarcomnicu I, Gille E and
Tanase C: Phytochemicals in cancer prevention: Modulating
epigenetic alterations of DNA methylation. Phytochem Rev.
18:1005–1024. 2019.
|
|
84
|
Hsieh HH, Kuo MZ, Chen IA, Lin CJ, Hsu V,
Huangfu WC and Wu TY: Epigenetic modifications as novel therapeutic
strategies of Cancer chemoprevention by phytochemicals. Pharm Res.
42:69–78. 2025.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Guney Eskiler G, Sahin E, Deveci Ozkan A,
Cilingir Kaya OT and Kaleli S: Curcumin induces DNA damage by
mediating homologous recombination mechanism in triple negative
breast cancer. Nutr Cancer. 72:1057–1066. 2020.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Choi YE and Park E: Curcumin enhances
poly(ADP-ribose) polymerase inhibitor sensitivity to chemotherapy
in breast cancer cells. J Nutr Biochem. 26:1442–1447.
2015.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Komar ZM, Ladan MM, Verkaik NS, Dahmani A,
Montaudon E, Marangoni E, Kanaar R, Nonnekens J, Houtsmuller AB,
Jager A and van Gent DC: Curcumin induces homologous recombination
deficiency by BRCA2 degradation in breast cancer and normal cells.
Cancers (Basel). 17(2109)2025.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Xie Q, Bai Q, Zou LY, Zhang QY, Zhou Y,
Chang H, Yi L, Zhu JD and Mi MT: Genistein inhibits DNA methylation
and increases expression of tumor suppressor genes in human breast
cancer cells. Genes Chromosomes Cancer. 53:422–431. 2014.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Donovan MG, Selmin OI, Doetschman TC and
Romagnolo DF: Epigenetic activation of BRCA1 by genistein in vivo
and triple negative breast cancer cells linked to antagonism toward
aryl hydrocarbon receptor. Nutrients. 11(2559)2019.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Sharma M and Tollefsbol TO: Combinatorial
epigenetic mechanisms of sulforaphane, genistein and sodium
butyrate in breast cancer inhibition. Exp Cell Res.
416(113160)2022.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Karimian A, Majidinia M, Moliani A, Alemi
F, Asemi Z, Yousefi B and Naghibi AF: The modulatory effects of two
bioflavonoids, quercetin and thymoquinone on the expression levels
of DNA damage and repair genes in human breast, lung and prostate
cancer cell lines. Pathol Res Pract. 240(154143)2022.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Gao X, Wang J, Li M, Wang J, Lv J, Zhang
L, Sun C, Ji J, Yang W, Zhao Z and Mao W: Berberine attenuates
XRCC1-mediated base excision repair and sensitizes breast cancer
cells to the chemotherapeutic drugs. J Cell Mol Med. 23:6797–6804.
2019.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Fang MZ, Wang Y, Ai N, Hou Z, Sun Y, Lu H,
Welsh W and Yang CS: Tea polyphenol (-)-epigallocatechin-3-gallate
inhibits DNA methyltransferase and reactivates methylation-silenced
genes in cancer cell lines. Cancer Res. 63:7563–7570.
2003.PubMed/NCBI
|
|
94
|
Mirza S, Sharma G, Parshad R, Gupta SD,
Pandya P and Ralhan R: Expression of DNA methyltransferases in
breast cancer patients and to analyze the effect of natural
compounds on DNA methyltransferases and associated proteins. J
Breast Cancer. 16:23–31. 2013.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Zhang X, Timmermann B, Samadi AK and Cohen
MS: Withaferin a induces proteasome-dependent degradation of breast
cancer susceptibility gene 1 and heat shock factor 1 proteins in
breast cancer cells. ISRN Biochem. 2012(707586)2012.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Hahm ER, Lee J, Abella T and Singh SV:
Withaferin A inhibits expression of ataxia telangiectasia and
Rad3-related kinase and enhances sensitivity of human breast cancer
cells to cisplatin. Mol Carcinog. 58:2139–2148. 2019.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Yu Y, Katiyar SP, Sundar D, Kaul Z, Miyako
E, Zhang Z, Kaul SC, Reddel RR and Wadhwa R: Withaferin-A kills
cancer cells with and without telomerase: Chemical, computational
and experimental evidences. Cell Death Dis. 8(e2755)2017.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Batra RN, Lifshitz A, Vidakovic AT, Chin
SF, Sati-Batra A, Sammut SJ, Provenzano E, Ali HR, Dariush A, Bruna
A, et al: DNA methylation landscapes of 1538 breast cancers reveal
a replication-linked clock, epigenomic instability and
cis-regulation. Nat Commun. 12(5406)2021.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Yang J, Xu J, Wang W, Zhang B, Yu X and
Shi S: Epigenetic regulation in the tumor microenvironment:
Molecular mechanisms and therapeutic targets. Signal Transduct
Target Ther. 8(210)2023.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Sherif ZA, Ogunwobi OO and Ressom HW:
Mechanisms and technologies in cancer epigenetics. Front Oncol.
14(1513654)2025.PubMed/NCBI View Article : Google Scholar
|
|
101
|
McCarthy-Leo C, Darwiche F and Tainsky MA:
DNA repair mechanisms, protein interactions and therapeutic
targeting of the MRN complex. Cancers (Basel).
14(5278)2022.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Gupta VK, Singh R and Sharma B:
Phytochemicals mediated signalling pathways and their implications
in cancer chemotherapy: Challenges and opportunities in
phytochemicals based drug development: A review. Biochem Comp.
5:1–5. 2017.
|
|
103
|
Alaouna M, Penny C, Hull R, Molefi T,
Chauke-Malinga N, Khanyile R, Makgoka M, Bida M and Dlamini Z:
Overcoming the challenges of phytochemicals in triple negative
breast cancer therapy: The path forward. Plants (Basel).
12(2350)2023.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Singh VK, Arora D, Ansari MI and Sharma
PK: Phytochemicals based chemopreventive and chemotherapeutic
strategies and modern technologies to overcome limitations for
better clinical applications. Phytother Res. 33:3064–3089.
2019.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Koklesova L, Jakubikova J, Cholujova D,
Samec M, Mazurakova A, Šudomová M, Pec M, Hassan STS, Biringer K,
Büsselberg D, et al: Phytochemical-based nanodrugs going beyond the
state-of-the-art in cancer management-targeting cancer stem cells
in the framework of predictive, preventive, personalized medicine.
Front Pharmacol. 14(1121950)2023.PubMed/NCBI View Article : Google Scholar
|
